News
-
-
-
-
-
PRESS RELEASE
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
Abivax to present four abstracts on obefazimod for ulcerative colitis at 19th ECCO Congress, including a sponsored symposium on emerging treatment mechanisms. Event details available on ECCO website -
-
PRESS RELEASE
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
Abivax updates obefazimod Phase 2b clinical program in Crohn’s disease following FDA feedback. Trial design modification to align with FDA recommendations. Patient enrollment to start in Q3 2024 -
PRESS RELEASE
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
Abivax, a clinical-stage biotechnology company, will host a virtual KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with ulcerative colitis on February 6, 2024. The event will feature discussions on the unmet medical need, current treatment landscape, and ongoing clinical development plans for obefazimod. The key speakers at the event will be Marla Dubinsky, MD, and Parambir Dulai, MD, who are both consultants for Abivax and members of the Steering Committee for the IBD Program. -
PRESS RELEASE
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
Abivax, a clinical-stage biotechnology company, provides its 2024 strategic outlook and key milestones, including the expected data read-outs and trial results for its lead drug candidate obefazimod in the treatment of ulcerative colitis and Crohn’s disease. The company also outlines its financial update and objectives for strengthening its product pipeline. Learn more about Abivax's priorities and milestones for 2024. -
-
Allied Universal Event Services Professional Winner of Golden State Warriors’ Champion Spotlight Annual Starting 5
-
Viking Capital Announces Closing of Latest 252 Unit Acquisition in Austin - San Antonio Corridor
-
Assays Confirm High-Grade Tarcoola Open Pit Extensions
-
Seismic Survey Reveals Tarcoola Goldfield Architecture
-
OTCQB Trading Secured with DTCC Registration Approval
-
Turkiye Garanti Bankasi A.S.: Prospectus – Summary
-
Turkiye Garanti Bankasi A.S.: Prospectus – Capital Markets Instrument Note
-
EQS-Adhoc: United Internet AG: Non-scheduled, non-cash impairment on Tele Columbus investment
-
Shelly Group: Successful placement of shares with participation of BIT Capital for targeted increase in free float
-
Extraordinary General Meeting of 12 June 2024 - All proposals of the Board of Directors were confirmed by the General Meeting
-
Monthly disclosure of the total number of shares and voting rights - 31/05/2024
-
Combined General Meeting, June 13, 2024
-
Europorte and Kerlink revolutionize freight by launching Track Value, the first logistics application using Kinéis IoT space connectivity
-
AXA: Information relating to the number of voting rights and shares making up the share capital on 31/05/2024
-
Declaration of voting rights at the end of May 2024